Fertility and Sterility
Volume 94, Issue 4 , Pages 1195-1201 , September 2010

Suppression of ovarian function by a combined oral contraceptive containing 0.02 mg ethinyl estradiol and 2 mg chlormadinone acetate given in a 24/4-day intake regimen over three cycles

  • Jürgen Spona, Ph.D.

      Affiliations

    • Vitalogic GmbH, Vienna, Austria
    • Corresponding Author InformationReprint requests: Jürgen Spona, Ph.D., Vitalogic GmbH, Czerningasse 10, 1020 Vienna, Austria (FAX: 43-1-877-91539).
    • ,
  • Natascha Binder, Ph.D.

      Affiliations

    • Grünenthal GmbH, Aachen, Germany
    • ,
  • Kornelia Höschen, M.Sc.

      Affiliations

    • Grünenthal GmbH, Aachen, Germany
    • ,
  • Wilfried Feichtinger, Ph.D.

      Affiliations

    • Institute for Sterility Treatment, Vienna, Austria

Received 17 April 2009 ,Revised 22 June 2009 ,Accepted 25 June 2009.

References 

  1. Combined oral contraceptives . A statement by the committee on safety of drugs. Br Med J. 1970;2:231–232
  2. Bettendorf G, Breckwoldtt M, Keller PJ, Kuhl H, Runnebaum B, Braendle W. Recommendations on oral contraception. Der Frauenarzt. 1997;38:1058–1062
  3. Jeffcoate TN. R.C.O.G. statement on oral contraceptives. Br Med J. 1970;2:293
  4. Hoogland HJ, Skouby SO. Ultrasound evaluation of ovarian activity under oral contraceptives. Contraception. 1993;47:583–590
  5. Spona J, Binder N, Höschen K, Feichtinger W. Contraceptive efficacy and safety of a low-dose oral contraceptive, (0.03 mg ethinyl oestradiol and 2 mg chlormadinone acetate) Belara®, over three medication cycles. Eur J Contracept Reprod Health Care. 2008;13:39–48
  6. Spona J, Feichtinger W, Kindermann C, Moore C, Mellinger U, Walter F, et al. Modulation of ovarian function by an oral contraceptive containing 30 micrograms ethinyl estradiol in combination with 2.00 mg dienogest. Contraception. 1997;56:185–191
  7. Spona J, Feichtinger W, Kindermann C, Wunsch C, Brill K. Inhibition of ovulation by an oral contraceptive containing 100 micrograms levonorgestrel in combination with 20 micrograms ethinylestradiol. Contraception. 1996;54:299–304
  8. Sullivan H, Furniss H, Spona J, Elstein M. Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 microg) and ethinyl estradiol (15 microg) on ovarian activity. Fertil Steril. 1999;72:115–120
  9. Endrikat J, Cronin M, Gerlinger C, Ruebig A, Schmidt W, Dusterberg B. Open, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day oral contraceptive regimen with 20 microg ethinyl estradiol and 75 microg gestodene and a 21-day regimen with 20 microg ethinyl estradiol and 150 microg desogestrel. Contraception. 2001;64:201–207
  10. Spona J, Elstein M, Feichtinger W, Sullivan H, Ludicke F, Muller U, et al. Shorter pill-free interval in combined oral contraceptives decreases follicular development. Contraception. 1996;54:71–77
  11. Klipping C, Duijkers I, Trummer D, Marr J. Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen. Contraception. 2008;78:16–25
  12. Rapkin AJ, Sorger SN, Winer SA. Drospirenone/ethinyl estradiol. Drugs Today (Barc). 2008;44:133–145
  13. Plewig G, Cunliffe WJ, Binder N, Hoschen K. Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled phase III trial. Contraception. 2009;80:25–33
  14. Schramm G, Steffens D. Contraceptive efficacy and tolerability of chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg (Belara). Results of a post-marketing surveillance study. Clin Drug Invest. 2002;22:221–231
  15. Schramm G, Steffens D. A 12-month evaluation of the CMA-containing oral contraceptive Belara: efficacy, tolerability and anti-androgenic properties. Contraception. 2003;67:305–312
  16. Winkler U, Daume E, Sudik R, Oberhoff C, Bier U, Hallmann C, et al. A comparative study of the hemostatic effects of two monophasic oral contraceptives containing 30 mu(g) ethinylestradiol and either 2 mg chlormadinone acetate or 150 mu(g) desogestrel. Eur J Contracept Reprod Health Care. 1999;4:145–154
  17. Zahradnik HP, Goldberg J, Andreas JO. Efficacy and safety of the new antiandrogenic oral contraceptive Belara. Contraception. 1998;57:103–109
  18. Zahradnik HP, Hanjalic-Beck A. Efficacy, safety and sustainability of treatment continuation and results of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg chlormadinone acetate, in long-term usage (up to 45 cycles)—an open-label, prospective, noncontrolled, office-based Phase III study. Contraception. 2008;77:337–343
  19. Brucker C, Hedon B, The HS, Höschen K, Binder N, Christoph A. Long-term efficacy and safety of a monophasic combined oral contraceptive containing 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate administered in a 24/4-day regimen. Contraception. 2010;81:501–509
  20. Insler V, Glezerman M, Bernstein D. Diagnosis and treatment of the cervical factor of infertility. Reproduccion. 1981;5:295–300
  21. Insler V, Melmed H, Eichenbrenner I, Serr D, Lunenfeld B. The cervical score. Int J Gynaecol Obstet. 1972;10:223–228
  22. Worret I, Arp W, Zahradnik HP, Andreas JO, Binder N. Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trial with EE/CMA (Belara) and EE/LNG (Microgynon). Dermatology. 2001;203:38–44
  23. Endrikat J, Cronin M, Gerlinger C, Ruebig A, Schmidt W, Dusterberg B. Double-blind, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day versus a 21-day low-dose oral contraceptive regimen containing 20 microg ethinyl estradiol and 75 microg gestodene. Contraception. 2001;64:99–105
  24. Ludicke F, Sullivan H, Spona J, Elstein M. Dose finding in a low-dose 21-day combined oral contraceptive containing gestodene. Contraception. 2001;64:243–248
  25. Baerwald AR, Pierson RA. Ovarian follicular development during the use of oral contraception: a review. J Obstet Gynaecol Can. 2004;26:19–24
  26. Fitzgerald C, Feichtinger W, Spona J, Elstein M, Ludicke F, Muller U, et al. A comparison of the effects of two monophasic low dose oral contraceptives on the inhibition of ovulation. Adv Contracept. 1994;10:5–18
  27. Killick SR. Ovarian follicles during oral contraceptive cycles: their potential for ovulation. Fertil Steril. 1989;52:580–582
  28. Cohen BL, Katz M. Pituitary and ovarian function in women receiving hormonal contraception. Contraception. 1979;20:475–487
  29. Duijkers IJ, Klipping C, Verhoeven CH, Dieben TO. Ovarian function with the contraceptive vaginal ring or an oral contraceptive: a randomized study. Hum Reprod. 2004;19:2668–2673
  30. Bitzer J. Belara—proven benefits in daily practice. Eur J Contracept Reprod Health Care. 2005;10(Suppl 1):19–25
  31. Curran MP, Wagstaff AJ. Ethinylestradiol/chlormadinone acetate. Drugs. 2004;64:751–760discussion 61–2
  32. Zahradnik HP. Belara—a reliable oral contraceptive with additional benefits for health and efficacy in dysmenorrhoea. Eur J Contracept Reprod Health Care. 2005;10(Suppl. 1):12–18
  33. Endrikat J, Hite R, Bannemerschult R, Gerlinger C, Schmidt W. Multicenter, comparative study of cycle control, efficacy and tolerability of two low-dose oral contraceptives containing 20 microg ethinylestradiol/100 microg levonorgestrel and 20 microg ethinylestradiol/500 microg norethisterone. Contraception. 2001;64:3–10

 J.S. has nothing to disclose. N.B. has nothing to disclose. K.H. has nothing to disclose. W.F. has nothing to disclose.

 This study was designed, conducted and funded by Grünenthal GmbH. The Principle Investigator was Wilfried Feichtinger, M.D., and the Scientific Advisor was Jürgen Spona, Ph.D.

PII: S0015-0282(09)01431-9

doi: 10.1016/j.fertnstert.2009.06.057

Fertility and Sterility
Volume 94, Issue 4 , Pages 1195-1201 , September 2010

Article Tools

* Image Usage & Resolution